Intranasal GnRH agonist decapeptide used for endometriosis and central precocious puberty.
GnRH agonist administered intranasally twice daily. Continuous receptor occupancy downregulates pituitary GnRH receptors.
Evidence summary in progress. See the citations section below for the underlying research papers.
Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.
No documented drug interactions on file.
FDA approved for endometriosis and central precocious puberty (Synarel)
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
Showing 20 of 29 papers. View all on PubMed →